Concentration-QTcF Analysis of Quizartinib in Patients With Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)
|
Population Pharmacokinetics (PopPK) of Quizartinib and Its Active Metabolite AC886 in Patients With Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)
|
Development of a Physiologically Based Pharmacokinetic (PBPK) Model for Quizartinib and Evaluation of Drug-Drug Interaction (DDI) Risk as an Inhibitor of UDP-Glucuronosyltransferase 1A1 (UGT1A1)
|